Werewolf Therapeutics, Inc. (HOWL)
| Market Cap | 433.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 17.75M |
| EPS (ttm) | -36.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,931 |
| Open | 15.78 |
| Previous Close | 16.00 |
| Day's Range | 15.25 - 16.39 |
| 52-Week Range | 11.23 - 23.99 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 26.40 (+63.1%) |
| Est. Earnings Date | Nov 11, 2021 |
About HOWL
Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our molecules, which we refer to as INDUKINETM molecules, are intended to selectively target the tumor microenvironment, ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for HOWL stock is "Strong Buy." The 12-month stock price forecast is 26.40, which is an increase of 63.06% from the latest price.
News
Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutic...
Werewolf Therapeutics Inks Solid Tumor Trial Collaboration With Merck
Werewolf Therapeutics Inc (NASDAQ: HOWL) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK) to evaluate WTX-124 in combination with Keytruda (pembrolizu...
Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 INDUKINE™ Program
Werewolf Therapeutics to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule, in combination with KEYTRUDA® (pembrolizumab) as a treatment for pati...
Werewolf Therapeutics Reports Second Quarter 2021 Financial Results and Business Update
CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condit...
4 Global IPO Stocks Outperforming the S&P 500 Over the Past Month
In light of the global initial public offering market recording its strongest second quarter in two decades by volume and proceeds, four stocks that had their IPO during the past three months and outper...
Werewolf Therapeutics Announces Its Addition to the Russell 2000® Index
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...
Werewolf Therapeutics Reports First Quarter 2021 Financial Results
- Recently completed upsized initial public offering raising $120.0 million in gross proceeds - - Recently completed upsized initial public offering raising $120.0 million in gross proceeds -
Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics ...
Werewolf Therapeutics IPO: HOWL Stock Comes Out Howling on First Day of Trading
Werewolf Therapeutics (HOWL) stock is doing incredibly well for its first day of trading on the Nasdaq following its IPO. The post Werewolf Therapeutics IPO: HOWL Stock Comes Out Howling on First Day of...
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutic...
Werewolf Therapeutics looks to make a killing in the public markets with a $100M IPO
After banking $72 million at the start of the year, Werewolf Therapeutics now wants an IPO.
Werewolf Therapeutics IPO Registration Document (S-1)
Werewolf Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.